Using a new treatment to prevent infections in second-degree burn wounds
Official title: Treating Second-Degree Burn Wound Infections with a Quorum Sensing Inhibitor
Funded at Ionic Pharmaceuticals · NIH-10916626 · Data updated 2026-11-12
This study is testing a new gel that helps treat MRSA infections in burn wounds by blocking the bacteria's communication, making it easier for your body to fight the infection while being gentle and easy to use.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ionic Pharmaceuticals NIH-funded |
| Lab location | 1 site (Watertown, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R43AI183989-01 |
| Project ID | NIH-10916626 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with second-degree burn wounds who are at risk of developing MRSA infections.
✕Less likely to help
Patients with first-degree burns or those who do not have burn wounds may not benefit from this research.
What this research studies
This research investigates a novel approach to treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in second-degree burn wounds. The treatment focuses on inhibiting quorum sensing, a communication method used by bacteria to coordinate their behavior and increase virulence. By applying a topical hydrogel containing a natural product called w-hydroxyemodin, the researchers aim to disrupt this communication and enhance the body's immune response. The hydrogel dressing is designed to be easy to apply and remove, minimizing pain and discomfort for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for preventing infections in burn wounds, reducing complications and improving healing.
How similar studies have gone: While quorum sensing inhibition is a relatively novel approach, preliminary studies have shown promise in similar applications, indicating potential for success.
Where this research is happening
-
Ionic Pharmaceuticals
Watertown, United States Active
Researchers
- Principal investigator: Colby, Aaron Henry — Ionic Pharmaceuticals
- Study coordinator: Colby, Aaron Henry
Related research
Other NIH-funded projects on the same topics.
-
Diabetic Foot Ulcer Healing Network at the University of Arizona
A NIH-supported project at the University of Arizona aims to improve healing of diabetic foot ulcers by studying biomarkers and running high-quality clinical trials.
-
Understanding how skin layers coordinate healing after injury
Researchers are studying how different layers of adult skin coordinate rapid healing after injury to prevent infection and chronic wounds.
-
Immunomodulatory therapy to speed up healing after oral cavity injuries in kids
A new approach using a drug called FTY720 aims to improve healing and reduce pain after oral injuries or palate surgery in children.
-
How diabetic wounds let Group B Streptococcus cause infections
Researchers are learning how high blood sugar, immune changes, and other bacteria in diabetic wounds help Group B Streptococcus grow and cause worse infections in people with diabetes.
-
Understanding how skin cells exchange harmful chemicals to cause injury and wound repair
A research project aims to uncover how certain chemical agents damage human skin and what happens in the early stages of blistering and inflammation.
-
Intestinal mucosal wound healing in humans
A patient-friendly look at how the lining of the gut repairs itself after injury and why this matters for conditions like inflammatory bowel disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.